These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 27659733)

  • 21. Antiretroviral drug resistance profiles and response to second-line therapy among HIV type 1-infected Ugandan children.
    Musiime V; Kaudha E; Kayiwa J; Mirembe G; Odera M; Kizito H; Nankya I; Ssali F; Kityo C; Colebunders R; Mugyenyi P
    AIDS Res Hum Retroviruses; 2013 Mar; 29(3):449-55. PubMed ID: 23308370
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HIV type 1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy.
    Pillay V; Pillay C; Kantor R; Venter F; Levin L; Morris L
    AIDS Res Hum Retroviruses; 2008 Nov; 24(11):1449-54. PubMed ID: 19000027
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Virological Suppression and Patterns of Resistance Amongst Patients on Antiretroviral Therapy at 4 Nigerian Military Hospitals.
    Babajide K; Ayemoba O; Terfa K; Ake J; Crowell TA; Adamu Y; Mohammed T; Okoye I; Odeyemi S; Crawford K; Hughes L; Akintunde E; Umar T; Hamm TE; Njoku OS
    Curr HIV Res; 2017; 15(2):146-151. PubMed ID: 28521719
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV Drug Resistance Mutations in Non-B Subtypes After Prolonged Virological Failure on NNRTI-Based First-Line Regimens in Sub-Saharan Africa.
    Kityo C; Thompson J; Nankya I; Hoppe A; Ndashimye E; Warambwa C; Mambule I; van Oosterhout JJ; Wools-Kaloustian K; Bertagnolio S; Easterbrook PJ; Mugyenyi P; Walker AS; Paton NI;
    J Acquir Immune Defic Syndr; 2017 Jun; 75(2):e45-e54. PubMed ID: 28129253
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence of Antiretroviral Drug Resistance in Patients Who Are Not Responding to Protease Inhibitor-Based Treatment: Results From the First National Survey in South Africa.
    Steegen K; Bronze M; Papathanasopoulos MA; van Zyl G; Goedhals D; Van Vuuren C; Macleod W; Sanne I; Stevens WS; Carmona SC
    J Infect Dis; 2016 Dec; 214(12):1826-1830. PubMed ID: 27923946
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HIV-1 drug resistance surveillance among parturient women on anti-retroviral therapy in the Eastern Cape, South Africa: Implications for elimination of mother-to-child transmission.
    Adeniyi OV; Obi CL; Goon DT; Iweriebor B; Ajayi AI; Lambert J; Okoh A
    J Clin Virol; 2019 Aug; 117():89-95. PubMed ID: 31255794
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Moderate Levels of Pre-Treatment HIV-1 Antiretroviral Drug Resistance Detected in the First South African National Survey.
    Steegen K; Carmona S; Bronze M; Papathanasopoulos MA; van Zyl G; Goedhals D; MacLeod W; Sanne I; Stevens WS
    PLoS One; 2016; 11(12):e0166305. PubMed ID: 27907009
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased acquired protease inhibitor drug resistance mutations in minor HIV-1 quasispecies from infected patients suspected of failing on national second-line therapy in South Africa.
    Obasa AE; Ambikan AT; Gupta S; Neogi U; Jacobs GB
    BMC Infect Dis; 2021 Feb; 21(1):214. PubMed ID: 33632139
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme.
    Orrell C; Walensky RP; Losina E; Pitt J; Freedberg KA; Wood R
    Antivir Ther; 2009; 14(4):523-31. PubMed ID: 19578237
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Surveillance of HIV-1 pol transmitted drug resistance in acutely and recently infected antiretroviral drug-naïve persons in rural western Kenya.
    Onywera H; Maman D; Inzaule S; Auma E; Were K; Fredrick H; Owiti P; Opollo V; Etard JF; Mukui I; Kim AA; Zeh C
    PLoS One; 2017; 12(2):e0171124. PubMed ID: 28178281
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Virological response, HIV-1 drug resistance mutations and genetic diversity among patients on first-line antiretroviral therapy in N'Djamena, Chad: findings from a cross-sectional study.
    Adawaye C; Fokam J; Kamangu E; Alio HM; Chahad AM; Susin F; Moussa AM; Bertin TH; Tidjani A; Vaira D; Moutschen M
    BMC Res Notes; 2017 Nov; 10(1):589. PubMed ID: 29126456
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rilpivirine, emtricitabine and tenofovir resistance in HIV-1-infected rilpivirine-naive patients failing antiretroviral therapy.
    Lambert-Niclot S; Charpentier C; Storto A; Fofana D; Soulie C; Fourati S; Wirden M; Morand-Joubert L; Masquelier B; Flandre P; Calvez V; Descamps D; Marcelin AG
    J Antimicrob Chemother; 2014 Apr; 69(4):1086-9. PubMed ID: 24302653
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysis.
    Ngo-Giang-Huong N; Jourdain G; Amzal B; Sang-a-gad P; Lertkoonalak R; Eiamsirikit N; Tansuphasawasdikul S; Buranawanitchakorn Y; Yutthakasemsunt N; Mekviwattanawong S; McIntosh K; Lallemant M;
    PLoS One; 2011; 6(11):e27427. PubMed ID: 22132100
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High Prevalence of Drug Resistance Mutations Among Patients Failing First-Line Antiretroviral Therapy and Predictors of Virological Response 24 Weeks After Switch to Second-Line Therapy in São Paulo State, Brazil.
    Matsuda EM; Coelho LPO; Romero GF; de Moraes MJ; Lopez-Lopes GIS; Morejon K; Campeas AE; Cabral GB; Brígido LFM
    AIDS Res Hum Retroviruses; 2018 Feb; 34(2):156-164. PubMed ID: 28969448
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: evidence from routine clinical practice in Cameroon.
    Takou D; Fokam J; Teto G; Santoro MM; Ceccherini-Silberstein F; Nanfack AJ; Sosso SM; Dambaya B; Salpini R; Billong SC; Gori C; Fokunang CN; Cappelli G; Colizzi V; Perno CF; Ndjolo A
    BMC Infect Dis; 2019 Mar; 19(1):246. PubMed ID: 30871487
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low Incidence of HIV-1C Acquired Drug Resistance 10 Years after Roll-Out of Antiretroviral Therapy in Ethiopia: A Prospective Cohort Study.
    Mulu A; Maier M; Liebert UG
    PLoS One; 2015; 10(10):e0141318. PubMed ID: 26512902
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acquired HIV drug resistance mutations on first-line antiretroviral therapy in Southern Africa: Systematic review and Bayesian evidence synthesis.
    Hauser A; Goldstein F; Reichmuth ML; Kouyos RD; Wandeler G; Egger M; Riou J
    J Clin Epidemiol; 2022 Aug; 148():135-145. PubMed ID: 35192922
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa.
    Wallis CL; Mellors JW; Venter WD; Sanne I; Stevens W
    J Acquir Immune Defic Syndr; 2010 Apr; 53(4):480-4. PubMed ID: 19801944
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen.
    Steegen K; Levin L; Ketseoglou I; Bronze M; Papathanasopoulos MA; Carmona S; Stevens W
    PLoS One; 2014; 9(5):e97067. PubMed ID: 24816790
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incidence and types of HIV-1 drug resistance mutation among patients failing first-line antiretroviral therapy.
    Luo XL; Mo LD; Su GS; Huang JP; Wu JY; Su HZ; Huang WH; Luo SD; Ni ZY
    J Pharmacol Sci; 2019 Apr; 139(4):275-279. PubMed ID: 30928089
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.